TOP > 外国特許検索 > METHOD FOR DETECTING PRECANCEROUS ORAL LESION

METHOD FOR DETECTING PRECANCEROUS ORAL LESION

外国特許コード F170009255
整理番号 S2015-1881-C0
掲載日 2017年10月18日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP075667
国際公開番号 WO 2017038939
国際出願日 平成28年9月1日(2016.9.1)
国際公開日 平成29年3月9日(2017.3.9)
優先権データ
  • 特願2015-172327 (2015.9.1) JP
発明の名称 (英語) METHOD FOR DETECTING PRECANCEROUS ORAL LESION
発明の概要(英語) Provided is a non-invasive method that enables the early detection, via large-scale screening, of a precancerous lesion that has a chance of developing oral cancer. This method, in which data for diagnosing a precancerous oral lesion in a patient is acquired by detecting the methylation of DNA in a gargled solution collected from the patient, is characterized in that said DNA is the DNA of a promoter region of the DNA of at least one of the following genes: RASSF1, DAPK1, CD44, BRCA2, FHIT, CDKN2A, HIC1, CASP8, RARβ, CDKN2B, CHFR, ATM, CDKN1B, BRCA1, and CADM1.
特許請求の範囲(英語) [claim1]
1. Was picked from the subject detecting the methylation of DNA in the gargling liquid which by in the subject of acquiring the data for diagnosing the cancer lesion before the buccal cavity being the method, DNA the group below the gene:
RASSF1 (Ras-related domain family member 1: Ras association domain family member 1, NM-170714.1),
DAPK1 (cell dead-related protein kinase 1: death-associated protein kinase 1, NM-004938.2),
CD44 (NM-001001391.1),
BRCA2 (breast cancer sensitivity gene 2: breast cancer susceptibility gene 2, NM-000059.3),
FHIT (fragile histidine three connected residue gene: fragile histidine triad gene and NM-002012.2),
CDKN2A ([saikurin] dependant kinase obstruction factor 2A: cyclin-dependant kinase inhibiter 2A and NM-058195.3),
HIC1 (hypermethylated in cancer 1, NM-006497.3),
CASP8 ([kasupaze] 8: caspase 8, NM-001080125),
RAR.beta. ([rechinoin] acid receptor I: retinoic acid receptor beta and NM-000965.3),
CDKN2B ([saikurin] dependant kinase obstruction factor 2B: cyclin-dependant kinase inhibiter 2B and NM-078487.2),
CHFR (indirect division checkpoint gene: checkpoint with forkhead and ring finger domains, E3 ubiquitin protein ligase and NM-001161344.1),
ATM (capillary expandability ataxia symptom-related gene mutation type: ataxia telangiectasia mutated and NM-000051.3),
CDKN1B ([saikurin] dependant kinase obstruction factor 1B: cyclin-dependant kinase inhibiter 1B and NM-004064.3),
BRCA1 (breast cancer sensitivity gene 1: breast cancer susceptibility gene 1, NM-007294.3), and
CADM1 (cell adhesion molecule 1: cell adhesion molecule 1, NM-001098517.1)
The empty it features that it is DNA of the promoter territory of the gene of 1 kinds or more which are selected, the above-mentioned method.
[claim2]
2. The fact that it compares with the methylation of DNA in the methylation of DNA which is detected, the contrast sample is included, method of claim 1 statement.
[claim3]
3. It is DNA of 1 kinds or more where DNA is selected from DNA of the promoter territory of RASSF1, DAPK1, CD44, BRCA2, FHIT, CDKN2A, and the HIC1 gene, claim method of 1 or 2 statements.
[claim4]
4. It is DNA of 1 kinds or more where DNA is selected from DNA of the promoter territory of RASSF1, DAPK1, CD44, and the BRCA2 gene, claim method of 1 or 2 statements.
[claim5]
5. It is DNA of 1 kinds or more where DNA is selected from DNA of the promoter territory of RASSF1, CD44, BRCA2, DAPK1, and the FHIT gene, claim method of 1 or 2 statements.
[claim6]
6. The methylation of DNA, is detection possible ones making use of the probe which possesses the nucleotide arrangement which is shown in the arrangement number 1-30, either of the claim 1-5 method of 1 section statements.
[claim7]
7. Cancer lesion before the buccal cavity is the white sheet symptom, either of the claim 1-6 method of 1 section statements.
[claim8]
8. The primer or the probe in order to detect the abnormality methylation of DNA which is selected from DNA of the promoter territory of RASSF1, DAPK1, CD44, BRCA2, FHIT, CDKN2A, HIC1, CASP8, RAR.beta., CDKN2B, CHFR, ATM, CDKN1B, BRCA1, and the CADM1 gene is included, the kit for detecting the cancer lesion before the buccal cavity.
[claim9]
9. The probe of 1 or more where it possesses the nucleotide arrangement which is shown in the arrangement number 1-30 is included, the kit of claim 8 statement.
[claim10]
10. Cancer lesion before the buccal cavity is the white sheet symptom, claim the kit of 8 or 9 statements.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KAGOSHIMA UNIVERSITY
  • 発明者(英語)
  • HAMADA TOMOFUMI
国際特許分類(IPC)
指定国 (WO201738939)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
特許の内容に興味を持たれた方、ライセンスをご希望の方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close